FIGURE 1.
PSG1 binds to plasma membrane proteoglycans. CHO-K1 (A), L929 (B), and their derived mutant cell lines CHO-pgsA-745 (C), sog9 (D), CHO-pgsD-677 (E), and gro2c (F) were treated with 30 μg/ml PSG1-Fc or the control protein FLAGFc followed by PE-conjugated anti-human Fcγ. The median fluorescence intensity (MFI) of each treatment is shown.